Koyfin Home > Directory > Health Care > Akebia Therapeutics > EBITDA / Interest Expenses

Akebia Therapeutics EBITDA / Interest Expenses Chart (AKBA)

Akebia Therapeutics annual/quarterly EBITDA / Interest Expenses from 2012 to 2020. EBITDA / Interest is the interest coverage ratio and measures the ability of a company to service its debt.
  • Akebia Therapeutics EBITDA / Interest Expenses for the quarter ending June 06, 2020 was $-8m a -7,786.55% increase of 629m year over year
  • Akebia Therapeutics EBITDA / Interest Expenses for the last 12 months ending June 06, 2020 was $-24m a -1,524.03% increase of 372m year over year
  • Akebia Therapeutics Annual EBITDA / Interest Expenses for 2019 was $-117m a 80.62% decrease of -94m from 2018
  • Akebia Therapeutics Annual EBITDA / Interest Expenses for 2013 was $-23m a 77.20% decrease of -17m from 2012
  • Akebia Therapeutics Annual EBITDA / Interest Expenses for 2012 was $-5m
Other Ratios Metrics:
  • Akebia Therapeutics Total Debt / Capital for the quarter ending December 12, 2018 was $2m a 99.29% increase of 2m year over year
  • Akebia Therapeutics Other Liabilities for the quarter ending December 12, 2018 was $95m a 0.76% increase of 1m year over year
  • Akebia Therapeutics Total Debt / Equity for the quarter ending December 12, 2018 was $2m a 99.31% increase of 2m year over year
View Chart On Koyfin

Quarterly AKBA EBITDA / Interest Expenses Data

06/2020$-8m
03/2020$-17m
12/2019$-53m
09/2019$-637m
12/2012$-2m

Annual AKBA EBITDA / Interest Expenses Data

2019$-117m
2013$-23m
2012$-5m